Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

BIOTECH: Investors spurn Regulus IPO  Join our daily free Newsletter

MENAFN - - 10/9/2012 10:48:56 AM

Digg This Article: http%3a%2f%2fwww.menafn.com%2fmenafn%2fqn_news_story.aspx%3fstoryid%3d6ba60784-60eb-4d15-ba56-15aa15368e88%26src%3dMWHEAD Share This Article: http%3a%2f%2fwww.menafn.com%2fmenafn%2fqn_news_story.aspx%3fstoryid%3d6ba60784-60eb-4d15-ba56-15aa15368e88%26src%3dMWHEAD Add to Delicious Seed this article Buzz this article Add to Reddit Add to furl Add to stumbleupon Add to Mixx!


BIOTECH: Investors spurn Regulus IPO

LA JOLLA, Oct 09, 2012 (Menafn - North County Times - McClatchy-Tribune Information Services via COMTEX) --With demand for its shares far below expectations, Regulus Therapeutics Inc. endured a frosty reception with its initial public stock offering.

The IPO, launched Thursday, is "an outright disaster," the investment site Seeking Alpha said Monday. Regulus filed for the offering on Aug. 17.

Regulus had originally priced the offering at 10 to 12 a share, then lowered its offering at the last minute to 4 each. To compensate for the lower price, Regulus increased the number of shares offered from 4.54 million to 11.25 million.

Regulus shares closed Monday at 4.44, a gain of 24 cents for the day.

The lack of enthusiasm is also unwelcome news for the company's founders, Isis Pharmaceuticals Inc. of Carlsbad and Alnylam Pharmaceuticals Inc. of Cambridge, Mass. They contributed promising technology based on RNA interference to Regulus, and stand to profit if Regulus succeeds.

RNA interference and a related technology pioneered by Isis called antisense share the potential of stopping diseases at their genetic roots. Regulus is developing drugs that regulate gene expression from RNA snippets called microRNAs.

Regulus has scored a couple of significant drug development partnerships, such as one announced Aug. 14 with AstraZeneca. Regulus will get 28 million from the deal, including an up-front payment and an equity investment.

However, the deals aren't a guarantee that Regulus will succeed in developing any drugs, at least not anytime soon. Regulus isn't expected to file an application to begin a clinical trial of a drug until 2014.

"The fact that the company is not generating any revenues from actual products at this time, and the foreseeable future, is freaking out investors," Seeking Alpha wrote. "Furthermore, the fact that insiders accepted significant dilution in the offering is a red flag as well."

Call staff writer Bradley J. Fikes at 760-739-6641.

___ (c)2012 the North County Times (Escondido, Calif.) Visit the North County
Times (Escondido, Calif.) at www.nctimes.com Distributed by MCT Information
Services


 






International Provider
May 19, 2013 DJ MARKET COMMENT: Base Metals Likely To Have Upward Bias N/T - BNPP, DowJones Select
May 19, 2013 Letters show rift over San Onofre nuclear repairs, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 GCC's petrochemical firms need to be flexible: Experts, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 5 STORYLINES TO WATCH FOR THIS WEEK, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 Teens take charge of restitution through mock trials, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 An accidental witness to history, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 BRIEF: HIGH SCHOOL TENNIS, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 Fake rescue mission turns real, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 Tour of California: Tejay van Garderen wins championship, McClatchy-Tribune Information Services -- Unrestricted
May 19, 2013 High school abroad Mount de Sales student goes overseas for education, McClatchy-Tribune Information Services -- Unrestricted
more...


 
MENAFN






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help